However, a recent study of IL-15-expressing GPC3 CAR-T cells reported that infusion of those CAR-T cells into a patient with hepatocellular carcinoma (HCC) led to grade 4 cytokine release syndrome (CRS), which could be controlled by administration of rimiducid to trigger apoptosis of CAR-T cells (40). This evidence concerns the gene GPC3 and hepatocellular carcinoma.